Jinwu Financial News | According to the Northeast Securities Research Report, Hehuang Pharmaceutical (00013) held a conference in Shanghai to share the latest research and development progress, and broadcast it live on the Internet simultaneously. At the conference, the company's senior management team shared the company's R&D strategy and vision, as well as some of the projects in the company's rich and innovative drug candidate pipeline, including the latest developments in products such as surufatinib, solepinib, and HMPL-306.
According to the bank, the company has recently progressed rapidly in R&D, showing excellent clinical data and competitive patterns, and continuously promoting product globalization, which is expected to continue to catalyze the improvement of the company's fundamental value. The company has abundant pipeline reserves, broad product market space, and continuous overseas sales. The bank expects the company to achieve revenue of 0.729/0.866/1 billion US dollars in 24-26, with earnings per share of -0.06/0.05/0.18 US dollars, maintaining the company's “buy” rating.